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Abstract
Objective The objective of this study was to evaluate the
cost effectiveness of no prophylaxis, primary prophylaxis
(PP), or secondary prophylaxis (SP) with granulocyte col-
ony-stimulating factors (G-CSFs), i.e., pegfilgrastim,
lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim
(6- and 11-day), to reduce the incidence of febrile neu-
tropenia (FN) in patients with stage II breast cancer
receiving TC (docetaxel, cyclophosphamide) and in
patients with non-Hodgkin lymphoma (NHL) receiving
R-CHOP (rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisone) over a lifetime horizon from a
Belgian payer perspective.
Methods A Markov cycle tree tracked FN events during
chemotherapy (3-week cycles) and long-term survival (1-
year cycles). Model inputs, including the efficacy of each
strategy, risk of reduced relative dose intensity (RDI), and
the impact of RDI on mortality, utilities, and costs (in €;
2014 values) were estimated from public sources and the
published literature. Incremental cost-effectiveness ratios
(ICERs) were assessed for each strategy for costs per FN
event avoided, life-year (LY) saved, and quality-adjusted
LY (QALY) saved. LYs and QALYs saved were dis-
counted at 1.5% annually. Deterministic and probabilistic
sensitivity analyses (DSAs and PSAs) were conducted.
Results Base-case ICERs for PP with pegfilgrastim relative
to SP with pegfilgrastim were €15,500 per QALY and
€14,800 per LY saved for stage II breast cancer and €7800
per QALY and €6900 per LY saved for NHL; other com-
parators were either more expensive and less effective than
PP or SP with pegfilgrastim or had lower costs but higher
ICERs (relative to SP with pegfilgrastim) than PP with
pegfilgrastim. Results of the DSA for breast cancer and
NHL comparing PP and SP with pegfilgrastim indicate that
the model results were most sensitive to the cycle 1 risk of
FN, the proportion of FN events requiring hospitalization,
the relative risk of FN in cycles C2 versus cycle 1, no
history of FN, and the mortality hazard ratio for RDI
(\90% vs C90% [for NHL]). In the PSAs for stage II
breast cancer and NHL, the probabilities that PP with
pegfilgrastim was cost effective or dominant versus all
other prophylaxis strategies at a €30,000/QALY willing-
ness-to-pay threshold were 52% (other strategies B24%)
and 58% (other strategies B24%), respectively.
Conclusion From a Belgian payer perspective, PP with
pegfilgrastim appears cost effective compared to other
prophylaxis strategies in patients with stage II breast cancer
or NHL at a €30,000/QALY threshold.
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Key Points for Decision Makers
In this model of febrile neutropenia in patients with
stage II breast cancer or non-Hodgkin lymphoma,
primary prophylaxis with pegfilgrastim appears cost
effective as compared to other prophylaxis strategies
at a €30,000 per quality-adjusted life-year threshold.
Compared with past models, this model used updated
data from a meta-analysis for efficacy measures,
included two cancer/chemotherapy scenarios, and
added lipegfilgrastim as a treatment strategy.
1 Introduction
Febrile neutropenia (FN), defined as an absolute neutrophil
count of\0.5 9 109/L, or\1.0 9 109/L predicted to fall
below 0.5 9 109/L within 48 h, with fever or clinical signs
of sepsis [1], is a serious adverse effect of chemotherapy
and can result in significant morbidity, mortality, and costs
[2, 3]. FN is also associated with suboptimal delivery of
chemotherapy and reduced relative dose intensity (RDI),
which adversely affects long-term cancer outcomes and
survival [4]. The risk of FN depends on both patient-
specific factors (e.g., cancer type and stage, co-morbidities,
and age) and the myelotoxicity of the chemotherapy regi-
men received [1].
Granulocyte colony-stimulating factors (G-CSFs) are
indicated to reduce the duration of neutropenia and the
incidence of FN in patients with non-myeloid malignancies
receiving myelosuppressive chemotherapy associated with
a clinically significant incidence of FN [5–8]. European
clinical practice guidelines recommend prophylaxis with
G-CSF when the risk of FN is high ([20%) based on either
chemotherapy regimen risk alone or a combination of
regimen risk and individual patient risk factors [1]. While
pegfilgrastim and lipegfilgrastim require only one admin-
istration per chemotherapy cycle, filgrastim and lenogras-
tim require daily administration until neutrophil counts
recover. Although an average of 10–11 doses of filgrastim
or lenograstim per chemotherapy cycle were effective in
clinical trials [9, 10], in clinical practice daily G-CSFs are
sometimes administered in shorter courses (i.e., four to six
doses), which can result in reduced effectiveness [11].
G-CSFs can be used as primary prophylaxis (PP) or sec-
ondary prophylaxis (SP); PP is defined as prophylactic
administration in the first cycle and every subsequent cycle
of chemotherapy, while SP is defined as initiation of pro-
phylaxis in the cycle immediately after the first cycle with
an FN event and continuing prophylaxis until the end of the
chemotherapy course.
Previously, Markov models have been used to examine
the cost effectiveness of FN prophylaxis strategies in
patients with early-stage breast cancer [12, 13], recurrent
ovarian cancer [14], and non-Hodgkin lymphoma (NHL)
[15, 16]. This model used updated data from a meta-anal-
ysis for efficacy measures [17], included two cancer/
chemotherapy scenarios, and added lipegfilgrastim as a
treatment strategy. The cost effectiveness of lipegfilgras-
tim, which was approved by the European Medicines
Agency in 2013 [7], has not been examined previously.
Our model was developed from a Belgian payer perspec-
tive to estimate the cost effectiveness of no prophylaxis,
PP, and SP with pegfilgrastim, lipegfilgrastim, filgrastim
(6- and 11-day courses), and lenograstim (6- and 11-day
courses) in patients with stage II breast cancer receiving
TC (docetaxel and cyclophosphamide) and patients with
NHL receiving R-CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone).
2 Methods
2.1 Model Structure
The model structure was adapted from previously pub-
lished cost-effectiveness models in FN [12, 14–16] and
includes clinically relevant elements (e.g., FN-related
mortality and RDI) that are reflective of real-world clinical
observations and practice. Both clinical and modeling
experts were consulted during the model development
process. More details on validation and testing of the
conceptual model, data inputs, computational model, and
operational validity are contained in the Technical
Appendix in the Electronic Supplementary Material.
The Markov cycle tree was developed in Microsoft
Excel 2010 to simulate FN events, RDI, and survival in
the treatment of stage II breast cancer patients receiving
TC (75 mg/m2 of docetaxel and 600 mg/m2 of
cyclophosphamide every 21 days for four cycles) and NHL
patients receiving R-CHOP (cyclophosphamide 750 mg/
m2 on day 1, doxorubicin 50 mg/m2 on day 1, vincristine
1.4 mg/m2 on day 1, prednisone 100 mg/day on days 1–5,
plus rituximab 375 mg/m2 on day 1 every 21 days for six
cycles). Initially, there was a decision whether to have no
prophylaxis or to initiate PP or SP (Fig. 1). If prophylaxis
was initiated, there was a decision as to which G-CSF to
use, i.e., pegfilgrastim, filgrastim (6- or 11-day),
lenograstim (6- or 11-day), or lipegfilgrastim. For each of
these choices, there was a chance of FN occurring during
the first chemotherapy cycle (cycle length = 3 weeks;
Fig. 1a). Following the decision tree, FN events were then
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tracked in chemotherapy cycles 2? (cycle
length = 3 weeks; Fig. 1b). After chemotherapy, long-
term cancer-related survival was tracked in Markov cycles
(cycle length = 1 year; Fig. 1c). Patients were categorized
by RDI of chemotherapy received. During each of these
cycles, patients could transition to different health states,
with each health state having a corresponding cost and
quality-of-life outcome. Markov cycles were repeated for
the lifetime of a patient; the model concluded when the
entire cohort died. Total costs and outcomes were summed
across cycles. Clinical inputs, costs (in euros (€); 2014
values), and utilities were estimated from peer-reviewed
publications, publicly available sources, and research
databases (Tables 1, 2).
2.2 Model Inputs
Model inputs were estimated based on data published in
English in peer-reviewed journals or publicly available
sources, as described in Sects. 2.2.1–2.2.6. We also used
data sources consistent with previously published cost-ef-
fectiveness models of FN [12, 14–16].
2.2.1 Febrile Neutropenia Risk
In a meta-analysis of 902 breast cancer patients receiving
TC from 13 studies, the pooled random-effects estimate of
chemotherapy course-level FN risk without primary G-CSF
prophylaxis was 29%. The baseline FN risk in cycle 1
(19%) was estimated by calibrating the model using Solver
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Fig. 1 Markov cycle tree with hypothetical cohorts of stage II breast
cancer patients receiving TC for four cycles and non-Hodgkin
lymphoma patients receiving R-CHOP for six cycles. Model struc-
ture: a decision tree (initial chemotherapy cycle and associated febrile
neutropenia events); b Markov phase 1 (subsequent chemotherapy
cycles after cycle 1); and c Markov phase 2 (post-chemotherapy
period). FN febrile neutropenia, M Markov, NHL non-Hodgkin
lymphoma, R-CHOP rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone, RDI relative dose intensity, TC docetaxel
and cyclophosphamide
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Table 1 Clinical parameters: granulocyte colony-stimulating factor efficacy and febrile neutropenia risk parameters for breast cancer and non-
Hodgkin lymphoma
Clinical parameters Base-case efficacy value
RR vs. no G-CSF (DSA range)
PSA SE, distribution type
Prophylaxis strategy
Pegfilgrastima [17] 0.29 (0.19–0.44) Log mean = -1.25,
SD = 0.21, LogNormal
Filgrastim (11-day)a [17] 0.44 (0.29–0.64) Log mean = -0.82,
SD = 0.20, LogNormal
Filgrastim (6-day) [11] 0.71 (0.37–1.00) SE = 0.17, beta
Lenograstim (11-day)a [17] 0.59 (0.39–0.81) Log mean = -0.52,
SD = 0.18, LogNormal
Lenograstim (6-day) [11] 0.71 (0.37–1.00) SE = 0.17, beta
Lipegfilgrastima [17] 0.39 (0.16–0.90) Log mean = -0.94,
SD = 0.44, LogNormal
No prophylaxis (baseline) 1.00 (NA) NA
FN risk parameters
RR of FN in cycles C2, history of FN vs. no history of FN [13, 53] 9.09 (6.19–13.35) Log mean = 2.21,
SD = 0.20, LogNormal
RR of FN in cycles C2 vs. cycle 1, no history of FN [13, 53] 0.21 (0.155–0.293) Log mean = -1.56,
SD = 0.16, LogNormal
Breast cancer-specific parameters
Cycle 1 FN risk—TC [18] 0.19 (0.16–0.24) SE = 0.02, beta
FN case-fatality (breast cancer) [2], SE based on average of Kuderer
et al. [3] and Dulisse et al. [54] (%)
3.4 (2.7–4.1) SE = 0.0037, beta
Mortality HR for RDI\85% vs. C85% (breast cancer) [24] 1.45 (1.00–2.32)b Log mean = 0.37,
SD = 0.215, LogNormal
Proportion of FN events that require hospitalization (breast cancer)
[39]
0.836 (0.19–1.00) SE = 0.02, beta
Probability of RDI\85%, age\65 years, no FN history (breast
cancer) [25] (%)
26.9 (NA) NA
OR for RDI\85%, age C65 vs.\65 years (breast cancer) [25] 1.51 (NA) NA
OR for RDI\85%, history of FN vs. no history of FN [25], SE based
on number and %
1.58 (1.18–2.07) Log mean = 0.457,
SD = 0.143, LogNormal
Length of FN hospitalization (breast cancer) [3] (days) 8.0 (7.6–8.4) NA
Mean height (breast cancer) [53] (m) 1.66 (1.54–1.78) SD = 0.06, normal
Mean weight (breast cancer) [53] (kg) 69 (41.6–96.4) SD = 14, normal
NHL-specific parameters
Cycle 1 FN risk—R-CHOP (assumed to be same as CHOP) [19] 0.21 (0.13, 0.29) SE = 0.04, beta
FN case-fatality (NHL) [2], SE from average of Kuderer et al. [3] and
Dulisse et al. [54] (%)
5.8 (5.1–6.5) SE = 0.0034, beta
Mortality HR for RDI\90% vs. C90% (NHL) [23] 2.083 (1.19–3.70) Log mean = 0.73,
SD = 0.29, LogNormal
Proportion of FN events that require hospitalization (NHL) [39] 0.836 (0.19–1.00) SE = 0.02, beta
Probability of RDI\90%, no FN history (NHL) [26] (%) 41.6 (NA) NA
Probability of RDI\90%, FN history (NHL) [26] (%) 70.6 (58.1–83.1) SE = 0.064, beta
Length of FN hospitalization (NHL) [3] (days) 10.7 (10.4–11.0) NA
Mean height (NHL) [53] (m) 1.72 (1.60–1.85) SD = 0.06, normal
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in Microsoft Excel, where the absolute difference
between the model-predicted risk at the end of four cycles
and the risk of FN over the course of the study described in
Younis et al. [18] was minimized. The FN risks in subse-
quent chemotherapy cycles (cycles 2–4) were calculated by
applying relative risks (RRs) of FN involving FN history in
any cycle(s) prior to the current cycle (described below).
Due to an absence of data for R-CHOP, the baseline FN
risk of R-CHOP in NHL in cycle 1 was assumed to be
equivalent to CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone) (21%), as based on a study of
elderly patients with aggressive NHL in which 205 patients
received CHOP [16, 19]. In the model, it was assumed that
54% of the NHL population was male [16].
The RRs of FN in subsequent chemotherapy cycles (i.e.,
cycles 2?) were obtained from Whyte et al. [13], as esti-
mated based on data for breast cancer patients [11]. The
RR of FN in cycles 2? versus cycle 1 for patients with no
FN history was 0.21, and the RR of FN in cycles 2? for
patients with an FN history versus no FN history was 9.09.
2.2.2 Efficacy with Granulocyte Colony-Stimulating
Factor Strategies
The base-case efficacy rates for pegfilgrastim, filgrastim
(11-day), lenograstim (11-day), and lipegfilgrastim were
obtained from a meta-analysis [17], with odds ratios (ORs)
converted to RRs (relative to no G-CSF prophylaxis)
(Table 1). In the meta-analysis [17], a mixed-treatment
comparison was used to assess the relative efficacy of PP
with different G-CSFs to reduce the incidence of FN in
cancer patients who received myelosuppressive
chemotherapy in 30 randomized controlled trials published
from 1990 to 2013. Efficacy estimates for filgrastim (6-
day) and lenograstim (6-day) relative to pegfilgrastim were
obtained from von Minckwitz et al. [11], in which data for
filgrastim (6-day) and lenograstim (6-day) were combined;
accordingly, efficacy estimates for 6-day filgrastim and
6-day lenograstim were assumed to be equivalent. For
patients with no history of FN, the risk of FN in
chemotherapy cycles 2? was calculated as the baseline
cycle 1 probability of FN, reduced when applicable by the
relative efficacy of prophylaxis, and multiplied by the
cycle 2? RR (0.21). For those patients with a history of
FN, this value was further multiplied by the FN history risk
multiplier (9.09).
2.2.3 Mortality Risk
During the on-chemotherapy phase of the model, patients
were assumed to be at risk of death from FN only, not from
cancer or other causes. FN case-fatality rates for breast
cancer (3.4%) and NHL (5.8%) were obtained from Cag-
giano et al. [2]. In the absence of data regarding the long-
term mortality due to breast cancer and NHL in Belgium,
data from the Netherlands Cancer Registry Database
[20, 21] were used to estimate the cancer-specific post-
chemotherapy mortality for years 1–10. Mortality rates for
years 11–20 were extrapolated by fitting the available data
to an exponential curve and applying the resulting constant
annual mortality rate. Patients alive 20 years after
chemotherapy were considered ‘cured’ and were subse-
quently subject to the same all-cause mortality rates as
those for the general population as per 2014 Belgian life
tables [22].
2.2.4 Relative Dose Intensity
Following completion of chemotherapy, patients were
stratified based on the RDI of chemotherapy received. RDI
thresholds of 85% for breast cancer and 90% for NHL were
selected as clinical data indicate that these are clinically
meaningful reductions in the delivered chemotherapy dose
intensity [23, 24]. The probabilities of an RDI\85% and
C85% for breast cancer and of an RDI\90% and C90%
for NHL depended on whether the patient experienced an
Table 1 continued
Clinical parameters Base-case efficacy value
RR vs. no G-CSF (DSA range)
PSA SE, distribution type
Mean weight (NHL) [53] (kg) 74.94 (45.4–104.5) SD = 15.08, normal
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, DSAs deterministic sensitivity analyses, FN febrile neutropenia, G-CSF
granulocyte colony-stimulating factor, HR hazard ratio, NA not applicable as not included in DSA and/or PSA (as denoted), NHL non-Hodgkin
lymphoma, OR odds ratio, PP primary prophylaxis, PSAs probabilistic sensitivity analyses, R-CHOP rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone, RDI relative dose intensity, RR relative risk, SD standard deviation, SE standard error, TC docetaxel and
cyclophosphamide
a For the base case, median values were obtained from Wang et al. [17]; for the PSA, the 95% confidence interval was used (e.g., for
lipegfilgrastim vs. pegfilgrastim OR). For Wang et al. [17], a mixed-treatment comparison was used to assess the relative efficacy of PP with
different G-CSFs to reduce the incidence of FN in cancer patients who received myelosuppressive chemotherapy in 30 randomized controlled
trials published from 1990 to 2013
b Lower bound truncated at 1.00
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Table 2 Costs for prophylaxis strategies and chemotherapy and utilities for breast cancer and non-Hodgkin lymphoma
Base-case value (DSA range) PSA SE, distribution type
Prophylaxis costa
Pegfilgrastim (6 mg injection)b (€) 1176.03 NA
Filgrastim (300 lg)b (€) 60.036
Filgrastim (480 lg)b (€) 83.964
Lenograstim (263 lg)b (€) 76.038
Lipegfilgrastimc (€) 1176.03
G-CSF administration costd (€) 6.22 (5.60–6.84h)
CBC costd (€) 9.32 (8.39–10.25h)
Percentage self-administering [38] (%) 20 (0–40)
Breast cancer—costs and utility values
Costse
TC chemotherapy costf (€) 519.09 (467–571h) NA
Breast cancer FN hospitalization cost [37] (€) 5317 (4785–5849h)
Breast cancer post-hospitalization FN cost [42] 32% of inpatient (1531–1872h)
Breast cancer outpatient FN cost [39] 16% of inpatient (766–936h)
Utility values
On chemotherapy [27]g 0.70 (0.55–0.83j) SE = 0.07, betaj
FN hospitalization, average of Brown and Hutton [30] and Brown et al. [31] 0.33 (0.27–0.40j) SE = 0.03, betaj
Post-chemotherapy, years 1–5 [33] 0.86 (0.65–0.98j) SE = 0.09, betaj
Post-chemotherapy, years 5? [34, 35] 0.96 (0.83–1.00k) SE = 0.05, betak
NHL—costs and utility values
Costse
R-CHOP chemotherapy costf (€) 1794.86 (1615–1974h) NA
NHL FN hospitalization cost [38] (€) 7183 (6465–7901h)
NHL post-hospitalization FN cost [42] 32% of inpatient (€2069–€2528h)
NHL outpatient FN cost [39] 16% of inpatient (€1034–€1264h)
Utility values
NHL on chemotherapy [28, 29]i 0.61 (0.49–0.73j) SE = 0.06, betaj
NHL FN hospitalization, average of Brown and Hutton [30] and Brown et al. [31] 0.33 (0.27–0.40j) SE = 0.03, betaj
NHL post-chemotherapy, year 1 [29] 0.79 (0.62–0.92j) SE = 0.08, betaj
NHL post-chemotherapy, years 2? [29] 0.89 (0.79–0.96k) SE = 0.04, betak
Unless otherwise indicated, the DSA range is based on 95% confidence intervals
BSA body surface area, CBC complete blood count, DSAs deterministic sensitivity analyses, FN febrile neutropenia, G-CSF granulocyte colony-stimulating
factor, NA not applicable as not included in the PSA, NHL non-Hodgkin lymphoma, NIHDI National Institute for Health and Disability Insurance, PSAs
probabilistic sensitivity analyses, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, SD standard deviation, SE standard error,
TC docetaxel and cyclophosphamide
a Filgrastim and lenograstim dosing is based on patient height and weight, with mean heights and weights of breast cancer and NHL patients calculated from
the studies in a meta-analysis [53]. Based on the mean height, weight, and a correlation coefficient of 0.50, a Dubois distribution was used to simulate the
proportion of patients with weights by cut points (60, 96, and 120 kg) and BSA\1.8 and C1.8 m2. Patients weighing\60, 60–96, 96–120, and[120 kg
were assumed to receive filgrastim 300, 480, 600, and 780 lg, respectively. Patients with BSA\1.8 m2 were assumed to receive one vial of lenograstim
263 lg, and those with BSA C1.8 m2 were assumed to receive two vials of lenograstim 263 lg
b NIHDI chapter 4 list prices, April 2014
c NIHDI chapter 4 list prices, August 2014
d NIHDI NomenSoft 2013
e The base-case FN hospitalization cost reflected the cost of FN-related hospitalization episodes for patients with breast cancer or NHL in Belgium [37, 38].
The post-hospitalization cost, reflecting ambulatory services, was calculated as 32% of the initial hospitalization cost [42]. FN events not requiring
hospitalization were assumed to be 16% of the FN hospitalization cost [39]
f Weighted average based on NIHDI chapter 4 list prices, March 2014
g The base-case utility estimate for breast cancer patients receiving chemotherapy was obtained from a focus group of oncology physician and nursing staff
using the visual analog scale
h DSA range is 90–110% of base-case value
i The base-case utility estimate for NHL patients was obtained from the European Quality of Life 5-Dimension (EQ-5D) questionnaire
j SE/SD not reported by studies; the range is based on assumption (assumed SE of 10% of base-case value)
k SE/SD not reported by studies; the range is based on assumption (assumed SE of 5% of base-case value)
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FN event during chemotherapy (Shayne et al. [25] and
Pettengell et al. [26], respectively), and also depended on
age for breast cancer [25]. Data from a study of women
with early-stage breast cancer were used to estimate the
mortality hazard ratio (HR) for patients with an RDI\85%
(HR = 1.45) [24]. The HR for NHL patients was based on
data for CHOP [23], for which there was an HR of 0.48 for
an average RDI of C90% versus\90%; the reciprocal HR
of 2.08 was used in the model. Separate annual probabili-
ties of death were calculated for those with an RDI C85%/
90% and\85%/90%, with weighted averages equal to the
overall mortality probabilities from the Netherlands Cancer
Registry Database [20, 21]. The HRs for mortality, 1.45
(breast cancer) and 2.08 (NHL), were subsequently applied
to patients with an RDI\85% (breast cancer) and\90%
(NHL) only.
2.2.5 Utilities
To calculate quality-adjusted life-years (QALYs), life-
years (LYs) were adjusted using utility values. Utility
values for chemotherapy, FN, and FN-related hospitaliza-
tion were estimated for consistency with Lyman et al.
[12, 15]. The base-case utility estimate for breast cancer
patients receiving chemotherapy was obtained from an
oncology physician and nursing staff focus group using the
visual analog scale (VAS) [27]. The base-case utility
estimate for NHL patients receiving chemotherapy was
obtained from Doorduijn et al. [28] and Uyl-de Groot et al.
[29]; these studies were conducted in The Netherlands/
Belgium, and the utilities were based on the European
Quality of Life–5 Dimension (EQ-5D) questionnaire. The
utilities associated with FN hospitalization for the breast
cancer and NHL analyses were estimated as an average of
Brown and Hutton [30] and Brown et al. [31] (estimates of
0.42 and 0.24, respectively, in breast cancer patients) and
were obtained from surveys of oncology nurses in the US
and UK, respectively, using the standard gamble technique.
In the model, this value is applied for the duration of FN
hospitalization (8 days for breast cancer and 10.7 days for
NHL as per Kuderer et al. [3]). An alternative analysis
incorporated an estimate from Lloyd et al. [32], who sug-
gest that the utility decrement of FN is 0.15; the utility of
FN was calculated by subtracting 0.15 from the baseline
utility of having cancer and receiving chemotherapy (0.70
for stage II breast cancer and 0.61 for NHL).
Patients were also assigned post-chemotherapy long-
term utilities in the first and subsequent years; breast cancer
estimates were based on a US study in which utility values
were assigned to each health state in the Armstrong model
by 30 internists [33]. Data obtained from Liljegren et al.
[34] and de Haes et al. [35] were used to estimate the post-
chemotherapy utility in years 5? for breast cancer patients;
health states were valued by 27 health professionals (in-
cluding 12 breast cancer experts) using the VAS; the
estimate represents the utility of being disease-free[1 -
year after breast-conserving therapy. Consistent with
Lyman et al. [15] in the NHL analyses, the post-
chemotherapy utility estimates were obtained from Uyl-de
Groot et al. [29] and were also based on the EQ-5D
questionnaire.
2.2.6 Costs
All costs are presented in 2014 (€); cost estimates were
inflated to 2014 values using the official Belgian Health
Index. Where possible, official published prices were used.
For drug costs, the official prices in the ambulatory setting
were used, as published on the website of the Belgian
Federal Institute for Sickness and Invalidity Insurance
(http://www.riziv.fgov.be/). For medical services such as
the administration of drugs or laboratory tests (e.g., com-
plete blood count [CBC]), costs were also used as available
on the same website. Costs related to hospitalization for FN
treatment are from previous publications and were based
on data from Moeremans et al. [36] as actualized in Somers
et al. [37] (costs for treating FN in breast cancer patients in
Belgium) and in Verhoef et al. [38] (costs for treating FN
in NHL patients in Belgium). For the readers’ information,
these three references have been included in a Technical
Appendix in the Electronic Supplementary Material. Costs
described in Moeremans et al. [36] included costs for
hospitalization, use of antimicrobials, infusions, laboratory
tests, interventions, and other medications. Drug acquisi-
tion and other costs are listed in Table 2. These drug
acquisition costs included a small capped margin for
pharmacy costs of preparation and delivery. Pegfilgrastim
was assumed to be administered once per chemotherapy
cycle, and patients were assumed to receive one CBC the
day before each chemotherapy cycle began [5]. For fil-
grastim, the summary of product characteristics (SPC) [6]
recommends one CBC prior to chemotherapy and two per
week during filgrastim therapy; thus, 6-day filgrastim was
associated with three CBCs, and 11-day filgrastim was
associated with five CBCs. Lenograstim was assumed to
have the same CBC schedule as filgrastim. The SPC for
lipegfilgrastim [7] indicates that a white blood cell count
should be performed at regular intervals during therapy; it
was assumed that lipegfilgrastim was associated with one
CBC prior to chemotherapy and one CBC during each
chemotherapy cycle. It was estimated that 20% of patients
self-administered [38]; these patients accordingly did not
incur administration costs. It was also estimated that 83.6%
of FN cases would require hospitalization in both the breast
cancer and NHL analyses [39]. Although two US studies
[39, 40] report that approximately 83% of FN events
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require hospitalization, Gerlier et al. [41] estimated that
19% of FN episodes for patients receiving PP required
hospitalization based on estimates from clinical experts in
Belgium. Accordingly, a lower bound of 19% for the
percentage of FN events requiring hospitalization was used
in the deterministic sensitivity analysis (DSA).
FN cost estimates were based on two original resources:
the Moeremans et al. [36] 2005 study with a chart review
of FN hospitalization costs in Belgium and the All Patient
Refined Diagnosis-Related Group (APR-DRG) 660 costs
obtained from the official source (http://www.tct.fgov.be),
both actualized to 2014 costs. These source data have also
been described in two previous studies [37, 38]. Specifi-
cally, the base-case FN hospitalization cost reflected the
cost of FN-related hospitalization episodes for patients
with breast cancer or NHL in Belgium [37, 38]. For out-
patient FN and post-hospitalization costs, as specific Bel-
gian costs were not available, proportional cost estimates in
comparison to FN hospitalization costs from the USA
[39, 42] were used as the best-referenced estimates avail-
able. The post-hospitalization cost, reflecting ambulatory
services, was calculated as 32% of the initial hospitaliza-
tion cost [42]. FN events not requiring hospitalization were
assumed to be 16% of the FN hospitalization cost [39].
2.3 Analyses
All analyses were performed from the payer perspective
and therefore included direct healthcare costs only.
Expected lifetime costs (excluding cancer care costs other
than those specified as being included, e.g. chemotherapy,
hospitalization, etc.), LYs, and QALYs were estimated for
each strategy. Cost effectiveness was assessed in terms of
incremental cost per FN event avoided, incremental cost
per LY saved, and incremental cost per QALY saved. Per
the Belgian guidelines, LYs and QALYs were discounted
at a rate of 1.5% per year [43]. Alternative analyses were
performed using discount rates of 0 and 3%, reflecting
recommendations by health technology assessment (HTA)
authorities in other European countries [43, 44]. The dis-
count rate for costs in Belgium is 3% [43]; however, since
all costs were incurred in the first year of the model, costs
were not discounted in model analyses. A half-cycle cor-
rection was used [45].
If a more costly strategy provided no additional benefit
compared with an alternative strategy (i.e., was both more
costly and less effective), then it was said to be ‘domi-
nated’ by the alternative strategy, and no incremental cost-
effectiveness ratio (ICER) was calculated. If a more costly
strategy provided additional benefit, then the two strategies
were compared by dividing the additional cost (i.e.,
incremental cost) by the additional benefit (i.e., incre-
mental effectiveness). Weak dominance (or extended
dominance) occurred when the ICER for a strategy was
greater than that of a more costly alternative. Strategies that
were weakly dominated were excluded, and ICERs of the
remaining strategies were recalculated. The process of
exclusion and recalculation was repeated until no remain-
ing strategies were weakly dominated [45]. A willingness-
to-pay threshold of €30,000/QALY was used as the crite-
rion for acceptable cost effectiveness [46].
2.3.1 Sensitivity Analyses
One-way sensitivity analyses were performed only for the
cost-effectiveness analysis, with QALYs as the outcome
measure. For DSAs, key model parameters were varied
using 95% confidence intervals (CIs), standard errors, and
plausible ranges derived from published literature
(Tables 1, 2) to assess how univariate changes in key
model parameters and parameter uncertainty impacted
cost-effectiveness results. In addition to the DSAs, a sce-
nario analysis was performed using an alternative data
source for the baseline risk of FN (23.2%) [47].
Uncertainty in cost-effectiveness results was also
assessed by performing probabilistic sensitivity analyses
(PSAs) using second-order Monte Carlo simulations.
Uncertainty in key model parameters (e.g., efficacy,
baseline risk and RR of FN, RDI parameters, costs, and
utilities) was characterized by probability distributions
around the base-case values for each parameter. Parame-
ters of these distributions were derived from the published
literature, or plausible ranges were formulated when CIs
or ranges were not reported (Tables 1, 2). A random
number generator was used to draw parameter sets from
each distribution, and these sets were run through the
model to generate estimates of cost and effectiveness for
each treatment strategy. The process of drawing parame-
ters and running the model was repeated 1000 times. The
incremental cost per QALY was then calculated for each
set of parameter values as in the base case. PSA results
are presented in the form of cost-effectiveness accept-
ability curves, which show the fractions of the 1000
simulations in which examined strategies were incremen-
tally cost effective over a range of willingness-to-pay
thresholds. Of note, the PSA was first conducted using a
beta distribution with a 95% CI of 0.19–1.00 for the
proportion of FN events requiring hospitalization. To
further explore the uncertainty in the proportion of FN
events requiring hospitalization, an alternative PSA was
then performed using a uniform distribution assuming
lower and upper bounds of 0.19 and 1.
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3 Results
3.1 Base-Case Analyses
In patients with stage II breast cancer treated with TC, total
costs per patient ranged from €5037 (SP with pegfilgras-
tim) to €9005 (PP with 11-day lenograstim; Table 3). The
total number of FN events per patient ranged from 0.11 (PP
with pegfilgrastim) to 0.53 (no prophylaxis). The total
number of LYs ranged from 15.92 (no prophylaxis) to
16.18 (PP with pegfilgrastim), and the total number of
QALYs ranged from 15.01 (no prophylaxis) to 15.26 (PP
with pegfilgrastim). The ICERs for PP with pegfilgrastim
versus SP with pegfilgrastim were €9700 per FN event
avoided, €14,800 per LY saved, and €15,500 per QALY
saved. Other comparators were either dominated by PP or
SP with pegfilgrastim or eliminated via extended
dominance.
In patients with NHL treated with R-CHOP, total costs
per patient ranged from €16,387 (SP with pegfilgrastim) to
Table 3 Base-case cost-effectiveness results for stage II breast cancer treated with TC (docetaxel and cyclophosphamide) (incremental cost per









ICER (D cost/D FN) ICER (D cost/D LY) ICER (D cost/D
QALYs)
SP with pegfilgrastim 5037 0.361 16.014 15.099 Ref Ref Ref
SP with lipegfilgrastim 5226 0.386 16.001 15.085 Dominated Dominated Dominated
SP with filgrastim (11-day) 5252 0.398 15.994 15.079 Dominated Dominated Dominated
SP with filgrastim (6-day) 5287 0.463 15.959 15.045 Dominated Dominated Dominated
No prophylaxis 5340 0.534 15.920 15.008 Dominated Dominated Dominated
SP with lenograstim (6-day) 5412 0.463 15.959 15.045 Dominated Dominated Dominated
SP with lenograstim (11-day) 5705 0.436 15.974 15.059 Dominated Dominated Dominated
PP with filgrastim (6-day) 6233 0.334 16.040 15.123 Extended dominance Extended dominance Extended dominance
PP with lenograstim (6-day) 6992 0.334 16.040 15.123 Dominated Dominated Dominated
PP with filgrastim (11-day) 7117 0.182 16.133 15.213 Extended dominance Extended dominance Extended dominance
PP with pegfilgrastim 7482 0.109 16.179 15.257 €9735 €14,832 €15,459
PP with lipegfilgrastim 7806 0.158 16.148 15.227 Dominated Dominated Dominated
PP with lenograstim (11-day) 9005 0.266 16.081 15.163 Dominated Dominated Dominated
D incremental, FN febrile neutropenia, ICER incremental cost-effectiveness ratio, LYs life-years, PP primary prophylaxis, QALY quality-adjusted
life-year, Ref reference strategy, SP secondary prophylaxis
Table 4 Base-case cost-effectiveness results for non-Hodgkin lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin,









ICER (D cost/D FN) ICER (D cost/D LY) ICER (D cost/D
QALYs)
SP with pegfilgrastim 16,387 0.522 6.925 5.944 Ref Ref Ref
SP with lipegfilgrastim 16,858 0.576 6.905 5.927 Dominated Dominated Dominated
SP with filgrastim (11-day) 16,911 0.600 6.897 5.919 Dominated Dominated Dominated
SP with filgrastim (6-day) 17,312 0.736 6.847 5.875 Dominated Dominated Dominated
SP with lenograstim (6-day) 17,554 0.736 6.847 5.875 Dominated Dominated Dominated
No prophylaxis 17,747 0.882 6.795 5.829 Dominated Dominated Dominated
SP with lenograstim (11-day) 17,968 0.679 6.868 5.894 Dominated Dominated Dominated
PP with filgrastim (6-day) 18,170 0.538 7.024 6.031 Dominated Extended dominance Extended dominance
PP with filgrastim (11-day) 18,862 0.282 7.221 6.205 Extended dominance Extended dominance Extended dominance
PP with pegfilgrastim 19,149 0.164 7.327 6.299 €7724 €6865 €7782
PP with lenograstim (6-day) 19,297 0.538 7.024 6.031 Dominated Dominated Dominated
PP with lipegfilgrastim 19,801 0.243 7.255 6.235 Dominated Dominated Dominated
PP with lenograstim (11-day) 22,007 0.423 7.109 6.106 Dominated Dominated Dominated
D incremental, FN febrile neutropenia, ICER incremental cost-effectiveness ratio, LYs life-years, PP primary prophylaxis, QALY quality-adjusted
life-year, Ref reference strategy, SP secondary prophylaxis
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€22,007 (PP with 11-day lenograstim; Table 4). The total
number of FN events per patient ranged from 0.16 (PP with
pegfilgrastim) to 0.88 (no prophylaxis). The total number
of LYs ranged from 6.80 (no prophylaxis) to 7.33 (PP with
pegfilgrastim), and the total number of QALYs ranged
from 5.83 (no prophylaxis) to 6.30 (PP with pegfilgrastim).
ICERs for PP with pegfilgrastim versus SP with pegfil-
grastim were €7700 per FN event avoided, €6900 per LY
saved, and €7800 per QALY saved. Other comparators
were either dominated by PP or SP with pegfilgrastim or
eliminated via extended dominance.
3.2 Deterministic and Probabilistic Sensitivity
Analyses
DSAs were performed to determine which inputs the model
results were most sensitive to. For the DSA for stage II
breast cancer treated with TC (Fig. 2a), comparing PP
pegfilgrastim with SP pegfilgrastim, the model results were
most sensitive to cycle 1 risk of FN (ICER range
€9500–22,200), proportion of FN events requiring hospi-
talization (€13,900–21,800), and RR of FN in cycles C2
versus Cycle 1 (no history of FN) (€11,700–19,100).
Similar results were seen in the DSA for NHL treated with
R-CHOP (Fig. 2b); the model results were most sensitive
to cycle 1 risk of FN (€2200–19,500), mortality HR for an
RDI\90% versus C90% (€5700–13,300), and proportion
of FN events requiring hospitalization (€6400–13,200).
Results from the analyses based on an alternative data
source for the disutility of FN and with discount rates
ranging from 0 to 3% were similar to the base case. Using
an alternative data source for the probability of FN for the
TC regimen [47] resulted in an increase in the ICER for PP
with pegfilgrastim (vs. SP with pegfilgrastim) from
€15,500 to €24,100 per QALY.
We next performed PSA to examine the probabilities
that various prophylaxis strategies were cost effective. In
the PSA for stage II breast cancer treated with TC
(Fig. 2c), at a €30,000/QALY willingness-to-pay thresh-
old, the probability that PP with pegfilgrastim was cost
effective or dominant versus all other prophylaxis strate-
gies was 52.0%. The probabilities for other strategies were
23.6% for PP lipegfilgrastim, 14.0% for PP filgrastim
11-day, and 7.5% for PP filgrastim 6-day; all other strate-
gies had probabilities\3%. Similarly, in PSA of NHL
treated with R-CHOP (Fig. 2d), at a €30,000/QALY will-
ingness-to-pay threshold, the probability that PP with
pegfilgrastim was cost effective or dominant versus all
other prophylaxis strategies was 57.8%. The probabilities
for other strategies were 23.9% for PP lipegfilgrastim,
12.0% for PP filgrastim 11-day, and 4.7% for PP filgrastim
6-day; all other strategies had probabilities\2%. Results
of the PSA performed using a uniform distribution
(assuming lower and upper bounds of 0.19 and 1) for the
proportion of FN events requiring hospitalization indicate
that the probabilities that PP with pegfilgrastim, PP with
lipegfilgrastim, and PP with filgrastim (11-day) are cost
effective are 52.7, 19.8, and 15.2%, respectively, for breast
cancer and 59.8, 19.6, and 11.9%, respectively, for NHL.
4 Discussion
We found that PP with pegfilgrastim relative to SP with
pegfilgrastim was associated with ICERs of €15,500/
QALY for stage II breast cancer treated with TC and
€7800/QALY for NHL treated with R-CHOP; other com-
parators were either dominated by PP or SP with pegfil-
grastim or eliminated via extended dominance. Of note, for
both cancer/chemotherapy scenarios, while SP with peg-
filgrastim was on the cost-effectiveness frontier (i.e., not
dominated or eliminated via extended dominance) in the
base-case analysis, in the PSA, the probability that SP with
pegfilgrastim was cost effective at a willingness-to-pay
threshold of €30,000/QALY was\1%. Because PP and SP
with pegfilgrastim share many parameter values, the ICER
between these two strategies was not sensitive to changes
in those values.
Of interest to decision makers in Belgium, the PSAs
indicate that PP with pegfilgrastim was cost effective rel-
ative to SP with pegfilgrastim, lipegfilgrastim, filgrastim,
and lenograstim for both cancer/chemotherapy scenarios
when using a willingness-to-pay threshold of €30,000 per
QALY [46]. Specifically, based on the PSAs performed for
both cancer/chemotherapy scenarios, the probabilities that
PP with pegfilgrastim was cost effective at a threshold of
€30,000 per QALY were 52% for TC-treated stage II
breast cancer and 58% for R-CHOP-treated NHL. All other
strategies had probabilities of being cost effective of\25%
bFig. 2 Deterministic and probabilistic sensitivity analyses. a DSA
results for stage II breast cancer, TC (PP with pegfilgrastim vs. SP
with pegfilgrastim). b DSA results for NHL, R-CHOP (PP with
pegfilgrastim vs. SP with pegfilgrastim). In a and b, the vertical line
represents the base-case ICER, and the horizontal bars represent the
ranges of ICERs generated when the model was run using parameter
values between the high and low values of the plausible range for
each input considered. c PSA: cost-effectiveness acceptability curves
for stage II breast cancer, TC. d PSA: cost-effectiveness acceptability
curves for NHL, R-CHOP. In c and d, the willingness-to-pay
threshold in terms of €/QALY. € euros, BC base-case, DSA
deterministic sensitivity analysis, FN febrile neutropenia event, HR
hazard ratio, ICER incremental cost-effectiveness ratio, NHL non-
Hodgkin lymphoma, OR odds ratio, PP primary prophylaxis, PSA
probabilistic sensitivity analysis, QALY quality-adjusted life-year, R-
CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone, RDI relative dose intensity, RR relative risk, SP
secondary prophylaxis, TC docetaxel and cyclophosphamide
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(ranging from\1 to 24%). PSA results indicate that there
is an approximately 76–82% chance that PP with a pegy-
lated G-CSF is cost effective. The uncertainty lies in the
relative efficacy of pegfilgrastim and lipegfilgrastim, with
the evidence suggesting that pegfilgrastim is the cost-ef-
fective choice. The wide 95% CI for the lipegfilgrastim
versus pegfilgrastim OR (1.39 [95% CI 0.54–3.50]) [17] in
the PSA contributed to the finding that lipegfilgrastim had a
slightly more than 20% chance of being cost effective at a
threshold of €30,000/QALY. Results of DSAs for both
regimens indicate that model results were most sensitive to
the baseline risk of FN in cycle 1, as well as the proportion
of FN events requiring hospitalization and the RR of FN in
cycles C2 versus cycle 1 (no history of FN) for TC-treated
stage II breast cancer, and the mortality HR for an
RDI\90% and the proportion of FN events requiring
hospitalization for R-CHOP-treated NHL.
Previous analyses in the European setting examining FN
prophylaxis strategies in breast cancer came to similar
conclusions. In the UK, a study examining PP and SP of
filgrastim, lenograstim, and pegfilgrastim found that peg-
filgrastim was the most cost-effective strategy; whether PP
or SP was more cost effective depended on the individual
patient’s FN risk, age, cancer stage, and the price of G-CSF
[13]. Similar conclusions regarding the cost effectiveness
of PP with pegfilgrastim versus filgrastim have been
reported in other studies in the UK, France, and Italy
[48–50]. Here, we expanded on past analyses by including
lipegfilgrastim and using updated relative efficacy values
for all strategies, as based on a mixed-treatment compar-
ison analysis [17]. We also examined the various treatment
prophylaxis strategies in NHL. Thus, this model is aligned
with current HTAs, using updated relevant comparators
and evidence, and therefore is pertinent for reimbursement
decision making.
Several caveats should be kept in mind regarding these
results. The target populations were limited to patients with
stage II breast cancer receiving TC and patients with NHL
receiving R-CHOP. In the absence of data for NHL, breast
cancer data were employed for several parameters (e.g., RR
of FN in cycles 2? vs. cycle 1, RR of FN based on FN
history, and proportion of FN events requiring hospital-
ization). Costs of FN events not requiring hospitalization
and post-hospitalization FN costs were based on percent-
ages obtained from Weycker et al. [39], a study of meta-
static breast cancer, and Weycker et al. [42], a study of
multiple tumor types (including breast cancer and NHL).
The baseline risk of FN in cycle 1 was assumed to be the
same for R-CHOP and CHOP. Survival statistics were
based on Netherlands Cancer Registry data for the first
10 years and then extrapolated from 11 to 20 years to
capture long-term breast cancer and NHL survival. The
utility estimates used in the base-case analysis were
obtained from clinical staff (including a physician and
nurse focus group and a survey of oncology nurses) rather
than directly from patients or from applying a utility scale
based on community preferences such as the EQ-5D.
Unfortunately, no patient or EQ-5D data were available for
health states related to FN. Despite this limitation, DSAs
indicate that the model results were not sensitive to utility
values. Model comparators were limited to G-CSFs and did
not include antibiotics (antibacterials), as the European
Organisation for Research and Treatment of Cancer
(EORTC) guidelines indicate that antibiotic use in the
prevention of FN is controversial [1]. Regarding biosimi-
lars, the biosimilar filgrastim [NivestimTM (Hospira, a
Pfizer Company, Lake Forest, IL, USA)] entered the Bel-
gian market at the time of these analyses and was therefore
not included in the model. The two other biosimilars,
TevaGrastim (Teva, Petach Tikva, Israel) and Zarzio
(Sandoz, a Novartis Company, Princeton, NJ, USA), were
available in Belgium at identical prices as the originator,
and therefore are already covered in the model.
Although patients receiving G-CSFs had a higher inci-
dence of bone pain than patients receiving placebo in clinical
trials [5–8], adverse events related to G-CSF use were not
included in the model. The treatment for bone pain is anal-
gesics, which are inexpensive relative to the hospitalization
cost of FN, and the incidence of bone pain is similar for all
G-CSFs. Further, given the lifetime horizon, any disutility
associated with bone pain would be incurred for a relatively
short period of time. Accordingly, it was expected that
including bone pain would have a minimal impact on the
cost-effectiveness results. Two studies [51, 52] included
musculoskeletal pain in their analyses. However, results of
the DSA performed by Lee et al. [52] indicated that bone
pain did not have a significant impact on model results (bone
pain did not appear in the top 10 parameters of their DSA),
and bone pain did not appear to be a significant driver of
model results in the publication by Chan et al. [51]. Lastly,
for NHL, although in Bosly et al. [23] only an RDI\90%
was included in the multivariate model, the unadjusted
results also suggest shorter overall survival for those with an
RDI\85%. Of note, modeling mortality as a function of an
RDI\90% may only underestimate the complete effects of
reduced RDI.
5 Conclusion
We developed a model that simultaneously compares no
prophylaxis, PP, and SP with various G-CSF treatment
strategies. Assuming a willingness-to-pay threshold in
Belgium of €30,000/QALY [46], the results of our analyses
indicate that PP with pegfilgrastim should be considered
cost effective relative to other prophylaxis strategies for
436 K. Fust et al.
stage II breast cancer treated with TC and NHL treated
with R-CHOP.
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